RecruitingPhase 1Phase 2NCT07594522

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

Phase II Study of Ivonescimab Consolidation After Photon or Proton SBRT for Patients With Early-Stage NSCLC (I-PRECISE)

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

36 participants

Start Date

May 12, 2026

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ivonescimab and Photon or Proton standard stereotactic body radiotherapy (SBRT) for people with non-small cell lung cancer. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONPhoton or Proton standard stereotactic body radiotherapy (SBRT)

Radiation therapy to start within 28 days after enrollment. Radiation therapy will be performed in accordance with institutional standard practice. Proton therapy and photon therapy are allowed as per standard of care in accordance with institutional practice.

DRUGIvonescimab

Ivonescimab every 3 weeks on Day 1 of each Cycle as an intravenous (IV).